Search Results

resistance mutations to guide treatment selection. The FDA has a growing list of genomic biomarkers associated with specific drugs in the field of oncology that include targeted therapeutics, contraindications, clinical pharmacology, and clinical studies. NGS

treatment among cancer types. Establishing a potential core bacterial group that demarcates potential immunotherapy responders or nonresponders is an active area of investigation. Microbial Therapeutics The importance of the microbiome in CRC

Prognostic Scoring System [IPSS]) 10 or during follow-up (Dynamic IPSS [DIPSS], DIPSS plus; Table 1 ). 11 , 12 As important, the recognition of JAK-STAT dysregulation has led to the identification of novel therapeutics, culminating in the first approval

with 5.8 months for dabrafenib monotherapy ( P <.001). 8 Unfortunately, resistance to these agents inevitably develops and almost all patients experience disease progression within 2 years of therapy initiation. The second major class of therapeutics

standard therapeutics. Radiation, ADT, and chemotherapy could all work in concert with therapeutic cancer vaccines via numerous mechanisms to enhance clinical outcomes. 26 Immune-Based Therapies May Be Combined With Standard Therapies for More

Specialized Imaging Research Consortium (SIRC) aims to advance the treatment of patients with cancer through the clinical application of specialized imaging technologies. This is achieved by performing high-quality clinical trials of emerging therapeutics

decade, with the advent of sophisticated imaging and pathologic tests. 1 – 3 Especially in the era of tailored therapeutics, this presents both an opportunity and a challenge. CUP cancers can be approached in two distinct ways, and this may impact

significant disease progression, and he was transitioned to best supportive care and died 6 weeks later. Discussion As additional information is learned regarding the molecular mutations that drive oncogenesis, targeted therapeutics have played an

natural history of different genomic subtypes of glioblastoma is critical for the appropriate application of novel therapeutics. Here we demonstrate that a clinical-pathological database consisting of clinical and molecular data from patients with an

factors in MM, creating the need to revise the ISS in light of cytogenetic data and more modern therapeutics. Figure 1. ISS and R-ISS for multiple myeloma. Abbreviations: FISH, fluorescence in situ hybridization; ISS, International Staging System; LDH